3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
50
Carcinoma, Non-Small-Cell Lung
26
Squamous Cell Carcinoma of Head and Neck
25
Head and Neck Neoplasms
12
Neoplasm Metastasis
11
Neoplasms
10
Colonic Neoplasms
10
Rectal Neoplasms
9
Pancreatic Neoplasms
9
Lung Neoplasms
9
Mouth Neoplasms
6
Carcinoma, Squamous Cell
6
Carcinoma
6
Laryngeal Neoplasms
5
Hypopharyngeal Neoplasms
5
Oropharyngeal Neoplasms
4
Thyroid Neoplasms
3
Solid Tumors
3
Ovarian Neoplasms
3
Gastrointestinal Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Pancreatic Ductal
3
Breast Neoplasms
3
Sarcoma
2
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Laryngeal Diseases
2
mCRC
1
Urologic Neoplasms
1
Triple Negative Breast Neoplasms
1
Interventions
pembrolizumab
1
nazartinib
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Noonan Syndrome
×
Cetuximab
×
90 days
×
Clear all
NCT04670679
2026-03-25
FLAGSHP-1
Erasca, Inc.
Phase 1
Active not recruiting
90 enrolled